👩‍⚕️ Clinical reference for health professionals. This page summarises published clinical guidance and is not medical advice. Patients and members of the public: please don’t use this to make decisions about your own care — talk to your GP, pharmacist or treating team.
When to choose IV over oral: IV iron is indicated when oral iron is ineffective, not tolerated, or when rapid repletion is clinically needed. It is not first-line — trial oral iron first unless one of the situations below applies.
Select the clinical situation

✅ IV iron indicated

Documented intolerance to oral iron (GI side effects, nausea, constipation, abdominal pain) is a clear PBS-supported indication. Document that oral iron was trialled and not tolerated. A short trial of a different formulation (e.g. ferrous glycine sulphate, liquid iron) may be appropriate first but is not mandatory if intolerance is clear.

PBS criterion: "oral iron preparations are ineffective or cannot be used." Source: PBS Schedule March 2026.

✅ IV iron indicated

Malabsorption syndromes (coeliac disease, inflammatory bowel disease, post-bariatric surgery, gastric bypass, short bowel syndrome) impair oral iron absorption. IV iron bypasses the gut and is the appropriate route. Document the underlying diagnosis. Coeliac disease must be treated (gluten-free diet) alongside iron replacement.

  • Coeliac disease — confirm serological/histological diagnosis
  • Post-bariatric surgery — common indication; may need ongoing IV iron
  • IBD — IV preferred during active disease due to poor absorption and risk of GI irritation

✅ IV iron indicated — rapid correction needed

Pre-operative iron deficiency anaemia requiring rapid correction before surgery is a clear indication — "clinical need to deliver iron rapidly." IV iron raises haemoglobin faster than oral. Optimally given 2–4 weeks before surgery to allow erythropoiesis time to respond. Document the surgical date and clinical need for rapid correction.

PBS criterion: "clinical need to deliver iron rapidly." Source: PBS Schedule March 2026.

✅ IV iron indicated (with considerations)

IV iron in pregnancy is appropriate when oral iron is insufficient, not tolerated, or correction is needed rapidly (e.g. 3rd trimester IDA). Ferinject is now TGA-approved in children aged ≥1 year and adults; PBS eligibility applies to adults and children ≥1 year. Avoid IV iron in the first trimester unless benefits outweigh risks — discuss with obstetric team.

  • 2nd/3rd trimester IDA not responding to oral — strong indication
  • Document Hb, ferritin, gestational age
  • Monofer preferred by some clinicians in pregnancy — check current TGA PI

✅ IV iron indicated

Iron deficiency in CKD is common and oral iron is often poorly absorbed and tolerated. IV iron is standard of care in CKD patients on dialysis. In non-dialysis CKD, IV iron is appropriate when oral is ineffective or not tolerated. Erythropoiesis-stimulating agents (ESAs) require adequate iron stores. Usually co-managed with nephrology in CKD Stages 4–5.

Consult nephrologist for CKD Stage 4–5 or dialysis patients before initiating IV iron in GP.

✅ IV iron preferred in active IBD

In active inflammatory bowel disease, IV iron is preferred over oral — oral iron may exacerbate GI symptoms, is poorly absorbed during active inflammation, and may worsen mucosal disease. Even in remission, IV iron is appropriate if oral was not tolerated. Document disease activity status and prior oral iron trial.

  • Active disease: IV preferred regardless of oral tolerance
  • Remission: trial oral first; use IV if not tolerated or ineffective

✅ IV iron indicated — evidence-based in HFrEF

Iron deficiency (defined as ferritin <100 μg/L, OR ferritin 100–299 with transferrin saturation <20%) in heart failure with reduced ejection fraction (HFrEF) — IV iron (Ferinject) has Level I evidence for improving symptoms and reducing hospitalisation (AFFIRM-AHF trial). This is a recognised indication. Discuss with cardiology for complex patients.

AFFIRM-AHF: Ponikowski P et al. Lancet. 2020. Iron deficiency definition in HF: ferritin <100 μg/L OR ferritin 100–299 + TSAT <20%.

❌ IV iron generally not indicated

If oral iron has not been trialled, is being tolerated, and is correcting iron stores — IV iron is not routinely indicated on patient preference alone. IV iron carries small but real risks (anaphylaxis ~1:200,000, hypophosphataemia with Ferinject) and has a cost premium over oral iron. The PBS criterion requires that oral preparations are "ineffective or cannot be used."

Ensure the patient has trialled oral iron adequately (at least 4–8 weeks) before considering IV. If ineffective, document the ferritin trajectory and establish why oral is failing.

Both are PBS-listed for GP use in Australia. Monofer is generally preferred for high total dose requirements (>1000mg); Ferinject for most standard GP infusions. Source: PBS Schedule March 2026; RACGP AJGP May 2025.
Ferinject vs Monofer — key differences
FeatureFerinject (ferric carboxymaltose)Monofer (ferric derisomaltose)
PBS code3557K14081B
PBS cost (500mg)$54.63 PBS Mar 2026$122.74 PBS Mar 2026
PBS cost (1000mg)$109.25$245.48
Max single dose1000mg (or 20mg/kg) — hard limitNo single-dose limit — total dose in one session
Infusion time15 min (500mg), 30 min (1000mg)20 min (any dose)
Doses >1000mgSplit doses at least 7 days apartSingle session — practical advantage
Hypophosphataemia riskHigher — monitor in at-risk patientsLower risk
Age range (TGA)≥1 year (updated 2024)Adults only (≥18 years)
Preferred forStandard GP infusion, <1000mg required, paediatric (≥1yr)High total dose (>1000mg), convenience, bone disease
RACGP guidance (AJGP May 2025)Primary agent in AJGP practical guideNoted as alternative for high-dose GP setting
Ferinject hypophosphataemia: Ferric carboxymaltose (Ferinject) causes clinically significant hypophosphataemia in approximately 50–75% of patients given repeated high doses. For single infusions this is usually transient and subclinical. For patients requiring repeated infusions or those with baseline bone disease, consider Monofer or monitor phosphate. Source: RACGP AJGP May 2025.
PBS prescribing — Ferinject and Monofer
PBS criteria are from PBS Schedule March 2026. Authority prescription required. Criteria may be updated — verify at pbs.gov.au before prescribing.

Both products share the same PBS criterion: Treatment of iron deficiency in adults (and children ≥1 year for Ferinject) when oral iron preparations are ineffective or cannot be used, or when there is a clinical need to deliver iron rapidly. The diagnosis must be confirmed by laboratory tests.

Ferinject 3557K 500mg vial: $54.63
1000mg vial: $109.25
Max/dose: 1000mg
Authority: Required
Repeat: Authority each supply
Monofer 14081B 500mg vial: $122.74
1000mg vial: $245.48
Max/dose: No single-dose limit
Authority: Required
Repeat: Authority each supply

Concession patient copay: $7.70. General patient copay: $25.00. Pharmacy dispenses from stock or orders in advance — confirm availability when booking. Source: PBS Schedule March 2026.

GP workflow — initiating IV iron
1
Confirm diagnosis with labs

Ferritin, serum iron, transferrin saturation (TSAT), Hb. Document the result. PBS requires laboratory confirmation. Iron deficiency: ferritin <30 μg/L (or <100 μg/L in chronic disease/HF with TSAT <20%).

2
Establish IV iron indication

Document why oral iron is not appropriate: intolerance, malabsorption, rapid correction needed, CKD, IBD, cardiac. Record in notes — this supports the PBS authority claim.

3
Calculate dose

Simplified method (most GPs): if Hb ≥10 g/dL → 1000mg. If Hb <10 g/dL → 1500mg (given as two infusions ≥7 days apart). If Hb >14 g/dL → 500mg. Use our Iron Infusion Dosing Calculator for Ganzoni method or weight-based dosing.

4
Authority prescription + patient pharmacy run

Write PBS authority prescription. Patient fills at pharmacy before appointment — not every pharmacy stocks IV iron. Advise patient to call ahead. Most stock within 24–48 hours.

⚠️
No MBS item for GP iron infusion administration

There is currently no dedicated MBS item for IV iron administration in general practice. Bill: standard consultation item (23/36/44 based on time) + private procedure fee (typically $80–$150). The drug itself is PBS-funded. Source: MBS Book July 2026.

5
Administer — observe for 30 minutes post-infusion

Ferinject: 500mg over 15 min, 1000mg over 15–30 min. Anaphylaxis kit must be on hand. Observe for at least 30 minutes after infusion. Document batch numbers and reaction status.

6
Follow-up bloods at 4–8 weeks

Recheck ferritin and Hb to confirm response. Ferritin typically rises within 2 weeks. Hb response may take 4–8 weeks. Investigate if response is inadequate (ongoing blood loss, B12/folate deficiency, thalassaemia).

When to refer
  • Haematology — unexplained iron deficiency without clear cause, suspected haemolysis, thalassaemia, myelodysplasia
  • Gastroenterology — suspected GI blood loss (melaena, haematochezia, iron deficiency in men >50 or post-menopausal women without explanation)
  • Nephrology — CKD Stage 4–5 on dialysis, ESA therapy
  • Obstetrics — severe IDA in 1st trimester, or complex anaemia in pregnancy
  • Cardiology — iron deficiency in heart failure (HFrEF) for co-management decisions on IV iron frequency